The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists reported that the drug helped ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...
The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback